---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-020220"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:30:18.019197+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma enters amended employment agreements with CEO Josh Disbrow and CFO Mark Oki

## Summary
- CEO Disbrow’s agreement amended to one-year terms with auto-renewal; change of control acceleration requires termination within 12 months.
- CFO Oki’s agreement modified to conform equity acceleration and Cause definition changes including willful malfeasance standard.
- Cause definitions revised across both agreements: willful malfeasance/willful misconduct replaces material misconduct and gross negligence.
- Both amendments supersede prior employment agreements; terms approved by Compensation Committee.

## SEC filing metadata
- accession: 0001104659-23-020220
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000110465923020220/0001104659-23-020220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000110465923020220/tm236705d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-020220
- JSON: https://secwatch.observer/filing/0001104659-23-020220.json
- Plain text: https://secwatch.observer/filing/0001104659-23-020220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.